Medicare to Cover Wegovy for Heart Disease Risk, Not Weight Loss

The FDA-approved weight loss drug will now be accessible to Medicare enrollees at risk of heart disease, following a landmark clinical trial.

Medicare expands coverage to include the weight loss drug Wegovy for patients at risk of heart disease, following FDA approval.
Wegovy, a GLP-1 agonist, has gained popularity for its ability to reduce appetite and manage weight, but Medicare will only cover it for heart disease prevention.
The decision is based on a clinical trial showing Wegovy reduces the risk of heart problems in overweight individuals by 20%.
State Medicaid plans are also required to cover Wegovy for heart disease risk reduction, aligning with Medicare's new policy.
The coverage change could significantly increase access to Wegovy for millions of Americans, despite concerns about its high cost.